logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics targets opioids with post-op pain drug

Antibe Therapeutics (OTCQB: ATBPF) CEO Daniel Legault chats with Proactive Investors' Steve Darling at the 9th Annual LD Micro Invitational Investor Conference in Los Angeles, CA. The healthcare company focuses on the development of patents and out-licensing of improved compounds of existing drugs.

Quick facts: Antibe Therapeutics Inc

Price: 0.44 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $118.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ROBO Global team discuss its focus on innovation and key developments in AI

ROBO Global's director of research Jeremie Capron and strategic adviser Wyatt Newman discuss the firm's focus on technology innovation and the importance of taking a longer-term view when it comes to its investments. They also discuss what they consider to be some of the key upcoming...

1 hour, 50 minutes ago

2 min read